皮肤自发荧光与颈动脉粥样硬化斑块的关系研究

doi:10.12114/j.issn.1007-9572.2020.00.601

摘要/Abstract

摘要： 背景　颈动脉粥样硬化斑块是心脑血管疾病重要的危险因素，多用超声评价，但超声检查对设备、人员、经费要求较高。皮肤自发荧光（SAF）能够独立预测心脑血管事件发生及死亡等，操作简便、迅速、无创，因此探讨SAF与颈动脉粥样硬化斑块的关系对于颈动脉病变的预测有一定意义。目的　探讨在我国社区人群中SAF与颈动脉粥样硬化斑块病变的相关性。方法　2018年9—12月对北京某社区年龄>40岁的6 055例居民进行横断面调查研究，对所有受访者进行SAF检测、临床病史采集、体格检查、血液学检测及颈动脉B超检查。根据B超结果是否存在颈动脉粥样硬化斑块分为颈动脉粥样硬化斑块组和无颈动脉粥样硬化斑块组。以颈动脉粥样硬化斑块为因变量，以标准化性别、年龄、BMI、吸烟、糖尿病、高血压、脂代谢紊乱、高尿酸血症、慢性肾功能不全等传统心脑血管病变危险因素及SAF为自变量进行Logistic回归分析，探讨SAF对颈动脉粥样硬化斑块的影响。结果　6 055例调查对象B超提示存在颈动脉粥样硬化斑块者2 953例，无颈动脉粥样硬化斑块者3 102例。颈动脉粥样硬化斑块组SAF测量值为77.2（70.8，85.1） AU，明显高于无颈动脉粥样硬化斑块组SAF测量值73.4（68.0，80.1）AU （P<0.001）。Logistic回归分析结果显示，SAF是颈动脉粥样硬化斑块的影响因素〔OR=1.006，95%CI（1.000，1.012），P=0.043〕。以SAF值的第25、50、75百分位值69.2、75.1、82.4 AU为界，分为SAF低、中、高、明显升高4组，SAF明显升高组颈动脉粥样硬化斑块风险是SAF低值组的1.200倍〔OR=1.200，95%CI（1.012，1.423），P=0.036〕。亚组分析显示，校正传统心血管危险因素后，年龄<60岁人群中SAF明显升高组颈动脉粥样硬化斑块风险是SAF低值组的1.751倍〔OR=1.751，95%CI（1.270，2.415），P=0.001〕；吸烟人群中SAF明显升高组颈动脉粥样硬化斑块风险是SAF低值组的1.903倍〔OR=1.903，95%CI（1.297，2.792），P=0.001〕。结论　SAF与颈动脉粥样硬化斑块独立相关，在<60岁人群及吸烟人群中SAF明显升高者相比SAF低值者与颈动脉粥样硬化斑块相关性更明显。

关键词: 晚期糖基化终末产物, 皮肤自发荧光, 颈动脉粥样硬化斑块, 糖尿病, 年龄增长

Abstract: Background　Carotid atherosclerotic plaque is an important risk factor for cardiovascular and cerebrovascular diseases. Ultrasound is often used to evaluate carotid atherosclerotic plaque，but ultrasonic examination has relative high requirements on equipment，operator's ability and fund. Skin autofluorescence（SAF），a simple，rapid and non-invasive method，has a predictive value for cerebrovascular events and death. So we discussed the relationship between SAF value and carotid atherosclerotic plaque. Objective　To discuss the relationship between SAF value and carotid atherosclerotic plaque in community-dwelling Chinese populations. Methods　6 055 eligible residents aged over 40 in a Beijing community were invited to conduct a cross-sectional study from September 2018 to December 2018. SAF test，clinical history collection，physical examination，hematology test and carotid B-ultrasonography examination were performed in all subjects. According to the results of B-ultrasonography，the subjects were divided into carotid lesion group and non-carotid lesion group. With carotid lesion as dependent variable，and traditional risk factors of cardiovascular and cerebrovascular diseases such as standardized gender，age，BMI，smoking，diabetes，hypertension，dyslipidemia，hyperuricemia，chronic renal insufficiency and SAF as independent variables，Logistic regression analysis was performed to explore the relationship between SAF value and carotid atherosclerotic plaque. Results　Carotid lesion group（n=2 953） had much higher SAF value than non-carotid lesion group（n=3 102）〔77.2（70.8，85.1） AU vs 73.4（68.0，80.1） AU〕（P<0.001）. Binary Logistic regression analysis showed that SAF value was associated with the risk of carotid artery disease〔OR=1.006，95%CI（1.000，1.012），P=0.043〕. Analysis of subgroups stratified by quartiles of SAF value〔low（less than 69.2 AU），intermediate（greater than 69.2 but less than 75.1 AU），high（greater than 75.1 but less than 82.4 AU），very high（greater than 82.4 AU）〕 revealed that the risk of carotid artery lesion in very high SAF subgroup increased by a factor of 1.200〔OR=1.200，95%CI（1.012，1.423），P=0.036〕 compared with that of low SAF subgroup. Further analysis found that in people younger than 60 years，the risk of carotid artery disease in very high SAF subgroup was 1.751 times higher than that in low SAF subgroup〔OR=1.751，95%CI（1.270，2.415），P=0.001〕；in smokers，the risk of carotid artery disease in very high SAF subgroup was 1.903 times higher than that in low SAF subgroup〔OR=1.903，95%CI（1.297，2.792），P=0.001〕. Conclusion　SAF is independently associated with carotid atherosclerotic plaque. Significantly increased SAF is more significantly correlated with carotid artery lesions than low SAF in people under 60 years old or smokers.

Key words: Advanced glycation end products, Skin autofluorescence, Carotid artery atherosclerotic plaque disease, Diabetes, Aging

刘林,张健,刘薇,等. 皮肤自发荧光与颈动脉粥样硬化斑块的关系研究[J]. 中国全科医学, 2021, 24(4): 442-446. DOI: 10.12114/j.issn.1007-9572.2020.00.601.
LIU Lin,ZHANG Jian,LIU Wei, et al. Relationship between Skin Autofluorescence Value and Carotid Artery Atherosclerotic Plaque Disease　[J]. Chinese General Practice, 2021, 24(4): 442-446. DOI: 10.12114/j.issn.1007-9572.2020.00.601.

参考文献

［1］SINGH R，BARDEN A，MORI T，et al．Advanced glycation end-products：a review［J］．Diabetologia，2001，44（2）：129-146．DOI：10.1007/s001250051591.
［2］YOSHIOKA K．Skin autofluorescence is a noninvasive surrogate marker for diabetic microvascular complications and carotid intima-media thickness in japanese patients with type 2 diabetes：a cross-sectional study［J］．Diabetes Ther，2018，9（1）：75-85．DOI：10.1007/s13300-017-0339-3.
［3］YOZGATLI K，LEDFRANDT D，NOORDZIJ M J，et al．Accumulation of advanced glycation end products is associated with macrovascular events and glycaemic control with microvascular complications in type 2 diabetes mellitus［J］．Diabet Med，2018，35（9）：1242-1248．DOI：10.1111/dme.13651.
［4］RAJAOBELINA K，FARGES B，NOV S，et al．Skin autofluorescence and peripheral neuropathy four years later in type 1 diabetes［J］．Diabetes Metab Res Rev，2017，33（2）：e2832．DOI：10.1002/dmrr.2832.
［5］PAOLILLO R，MATTOS S，BORGHI-SILVA A，et al．Advanced glycation endproducts as biomarkers for risk of diabetes and cardiovascular diseases by skin autofluorescence：a noninvasive optical screening［J］．Photobiomodul Photomed Laser Surg，2019，37（3）：168-174．DOI：10.1089/photob.2018.4563.
［6］BLANC-BISSON C，VELAYOUDOM-CEPHISE L，COUGNARD-CREGOIRE A，et al．Skin autofluorescence predicts major adverse cardiovascular events in patients with type 1 diabetes：a 7-year follow-up study［J］．Cardiovasc Diabetol，2018，17（1）：82．DOI：10.1186/s12933-018-0718-8.
［7］MUKAI H，SVEDBERG O，LINDHOLM B，et al．Skin autofluorescence，arterial stiffness and Framingham risk score as predictors of clinical outcome in chronic kidney disease patients：a cohort study［J］．Nephrol Dial Transplant，2019，34（3）：442-448．DOI：10.1093/ndt/gfx371.
［8］CAVERO-REDONDO I，SORIANO-CANO A，ALVAREZ-BUENO C，et al．Skin autofluorescence-indicated advanced glycation end products as predictors of cardiovascular and all-cause mortality in high-risk subjects：a systematic review and meta-analysis［J］．J Am Heart Assoc，2018，7（18）：e009833．DOI：10.1161/JAHA.118.009833.
［9］许良元，刘勇，张弓，等．晚期糖基化终末产物荧光测量及其预校正技术研究［J］．光谱学与光谱分析，2010，30（1）：230-232．DOI：10.3964/j.issn.1000-0593(2010)01-0230-03.
［10］杨三梅，余锋，王贻坤，等．晚期糖基化终末产物荧光光谱检测法在糖尿病筛查中的应用研究［J］．激光生物学报，2011，20（1）：116-119，129．DOI：10.3969/j.issn.1007-7146.2011.01.022.
［11］VAN WAATERINGE P，MOOK-KANAMORI J，SLAGTER N，et al．The association between various smoking behaviors，cotinine biomarkers and skin autofluorescence，a marker for advanced glycation end product accumulation［J］．PLoS One，2017，12（6）：e0179330．DOI：10.1371/journal.pone.0179330.
［12］ISAMI F，WEST J，NAKAJIMA S，et al．Association of advanced glycation end products，evaluated by skin autofluorescence，with lifestyle habits in a general Japanese population［J］．J Int Med Res，2018，46（3）：1043-1051．DOI：10.1177/0300060517736914.
［13］KELLOW N，COUGHLAN M，REID C，et al．Association between habitual dietary and lifestyle behaviours and skin autofluorescence（SAF），a marker of tissue accumulation of advanced glycation endproducts（AGEs），in healthy adults［J］．Eur J Nutr，2018，57（6）：2209-2216．DOI：10.1007/s00394-017-1495-y.
［14］MEERWALDT R，GRAAFF R，OOMEN N，et al．Simple non-invasive assessment of advanced glycation endproduct accumulation［J］．Diabetologia，2004，47（7）：1324-1330．DOI：10.1007/s00125-004-1451-2.
［15］YAMAGISHI S，NAKAMURA N，SURMATSU M，et al．Advanced glycation end products：a molecular target for vascular complications in diabetes［J］．Mol Med，2015，21（1）：S32-40．DOI：10.1016/j.ijcard.2015.03.167.
［16］LUTGERS L，GRAAFF R，LINKS P，et al．Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes［J］．Diabetes Care，2006，29（12）：2654-2659．DOI：10.2337/dc05-2173.
［17］LIAURADO G，CEPERUELO-MALLAFRE V，VILARDELL C，et al．Advanced glycation end products are associated with arterial stiffness in type 1 diabetes［J］．J Endocrinol，2014，221（3）：405-413．DOI：10.1530/JOE-13-0407.
［18］JUJIC A，OSTLING G，PERSSON M，et al．Skin autofluorescence as a measure of advanced glycation end product levels is associated with carotid atherosclerotic plaque burden in an elderly population［J］．Diab Vasc Dis Res，2019，16（5）：466-473．DOI：10.1177/1479164119845319.

[1]	姚裕忠, 马晓骏, 宋懽, 钟瑜. 基于"全专精准管理"的糖尿病"1358模式"对社区糖尿病患者的管理效果研究[J]. 中国全科医学, 2023, 26(34): 4308-4314.
[2]	李殿江, 潘恩春, 孙中明, 文进博, 王苗苗, 武鸣, 沈冲. 社区2型糖尿病患者临床惰性现状及其影响因素分析[J]. 中国全科医学, 2023, 26(34): 4296-4301.
[3]	林恺, 姚弥, 陈章, 纪欣鑫, 林润琪, 陈永松, Sim MOIRA. 2型糖尿病治疗负担的概念框架及应对方式：基于视频记录分析[J]. 中国全科医学, 2023, 26(34): 4302-4307.
[4]	杨慧, 胡汝为, 刘汝青, 卢俊峰, 吴兢兰. 糖尿病患者社区卫生服务体验与血糖控制效果的关系研究[J]. 中国全科医学, 2023, 26(34): 4290-4295.
[5]	张娟, 李海芬, 李小曼, 姚苗, 马惠珍, 马强. 糖尿病足溃疡复发风险预测模型的构建：基于Logistic回归和支持向量机及BP神经网络模型[J]. 中国全科医学, 2023, 26(32): 4013-4019.
[6]	程经纬, 乔军军, 尹振, 胡俊鹏, 王庆贺, 柳杨青, 汪艳芳. 《2022 ISPAD临床实践共识指南：儿童和青少年糖尿病患儿运动》解读[J]. 中国全科医学, 2023, 26(30): 3719-3724.
[7]	周小琦, 刘新会, 张微, 李长风, 严亚琼. 老年人丙氨酸氨基转移酶和天冬氨酸氨基转移酶/丙氨酸氨基转移酶与2型糖尿病及代谢综合征的相关性研究[J]. 中国全科医学, 2023, 26(29): 3645-3649.
[8]	赵晓华, 杜林, 高胜男, 蒋子云. 老年糖尿病合并多发肌肉深部脓肿一例报道并文献分析[J]. 中国全科医学, 2023, 26(29): 3715-3718.
[9]	程晓冉, 张笑天, 李明月, 程昊哲, 汤皓晴, 郑汇娴, 张柏松, 刘晓云. 医防融合背景下慢性病随访对高血压和糖尿病患者健康行为及血压/血糖控制的影响研究[J]. 中国全科医学, 2023, 26(28): 3482-3488.
[10]	罗丹, 徐晶晶, 王玉冰, 李明子, FORBES Angus. 心理韧性导向的青少年1型糖尿病患者结构化治疗与教育课程的开发及初步实践[J]. 中国全科医学, 2023, 26(27): 3423-3429.
[11]	董亚楠, 姜晓锐, 王凯, 宗传冲, 林国栋, 李香卿, 林春晓, 迟俊涛. 改良胫骨横向骨搬运技术治疗Wagner 3~4级糖尿病足患者的效果研究[J]. 中国全科医学, 2023, 26(27): 3411-3416.
[12]	陈伦文, 周阳, 闫国栋, 沈怡, 孙晨, 蔡婉丽, 褚敏捷, 肖静. 2型糖尿病的恶性肿瘤风险：一项基于人群的前瞻性研究[J]. 中国全科医学, 2023, 26(26): 3238-3245.
[13]	费思杰, 张强, 刘方方, 白璐, 孙彩红, 信彩凤. 糖化血红蛋白变异性与2型糖尿病合并射血分数保留心力衰竭患者新发心房颤动的关系研究[J]. 中国全科医学, 2023, 26(26): 3246-3251.
[14]	卢作维, 曹宏伟, 刘涛, 张娜娜, 陈艳艳, 史勤利, 刘向阳, 王琼, 赖敬波, 李晓苗. 2型糖尿病患者微量白蛋白尿进展至大量白蛋白尿的风险预测模型研究[J]. 中国全科医学, 2023, 26(26): 3259-3268.
[15]	顾蕴杰, 宋静, 殷峻. 低碳饮食治疗内源性胰岛素缺乏糖尿病患者的临床研究[J]. 中国全科医学, 2023, 26(26): 3308-3313.